The Complex Regional Pain Syndrome (CRPS) pipeline includes over three key companies actively developing more than three treatment therapies, according to DelveInsight.
Complex Regional Pain Syndrome Overview:
Complex Regional Pain Syndrome (CRPS) is a persistent pain disorder that usually develops following trauma to a limb and can affect one or more limbs. It is categorized into Type I (without confirmed nerve injury) and Type II (with confirmed nerve damage). CRPS is recognized as a regional post-traumatic neuropathic pain condition, where the severity of symptoms often exceeds that of the initial injury. The condition affects roughly 26 individuals per 100,000, with a higher incidence in women (3.5:1) and is most commonly seen in people in their mid-thirties.
CRPS can result from a variety of injuries, including fractures, sprains, crush injuries, nerve damage, strokes, or surgical procedures, with approximately 91% of cases arising after surgery. The wrist is especially prone, particularly following distal radial fractures. The underlying cause is not fully understood but may involve immune system dysfunction, leading to nerve inflammation that disrupts blood flow, sensation, and temperature regulation.
There is no definitive test for CRPS, so diagnosis is primarily clinical and based on the Budapest Criteria. Additional assessments such as bone scans, X-rays, MRI, and specialized nerve imaging may aid in evaluating bone or nerve alterations. While there is no cure, early diagnosis and intervention are essential to managing symptoms, slowing disease progression, and enhancing patients’ quality of life.
Request for a detailed insights report on Complex Regional Pain Syndrome pipeline insights
“Complex Regional Pain Syndrome Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Complex Regional Pain Syndrome Therapeutics Market.
Key Takeaways from the Complex Regional Pain Syndrome Pipeline Report
-
DelveInsight’s Complex Regional Pain Syndrome (CRPS) pipeline report highlights a dynamic landscape, with more than three active companies developing over three therapeutic candidates for CRPS treatment.
-
Leading companies in this space, including Takeda, Tryp Therapeutics, and Soin Therapeutics, are actively exploring novel therapies to enhance the management of CRPS. Notable pipeline candidates in various stages of development include Soticlestat, TRP-8803, and others.
-
In March 2025, the North Queensland Persistent Pain Management Service was inaugurated at Townsville University Hospital. This $4.4 million center provides comprehensive care for chronic pain patients, including those with CRPS, offering both in-person and telehealth services.
-
In December 2025, the U.S. FDA granted Orphan Drug Designation to BRC-002, a botanically derived oral cannabinoid therapy developed by Biopharmaceutical Research Company (BRC). BRC-002 is designed to address CRPS-related pain along with associated comorbidities such as depression, anxiety, and sleep disturbances. Its safety and efficacy are currently being evaluated in a Phase 1 investigator-initiated trial, with plans to initiate Phase 2 by the end of 2025.
Complex Regional Pain Syndrome Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Complex Regional Pain Syndrome Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Complex Regional Pain Syndrome treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Complex Regional Pain Syndrome market.
Download our free sample page report on Complex Regional Pain Syndrome pipeline insights
Complex Regional Pain Syndrome Emerging Drugs
-
Soticlestat: Takeda
-
TRP-8803: Tryp Therapeutics
Complex Regional Pain Syndrome Companies
Approximately three or more leading companies are actively working on therapies for Complex Regional Pain Syndrome (CRPS). Among these, Takeda has the most advanced candidates, currently in Phase II clinical trials.
DelveInsight’s report covers around 3+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Complex Regional Pain Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Complex Regional Pain Syndrome Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Complex Regional Pain Syndrome Therapies and Key Companies: Complex Regional Pain Syndrome Clinical Trials and advancements
Complex Regional Pain Syndrome Pipeline Therapeutic Assessment
• Complex Regional Pain Syndrome Assessment by Product Type
• Complex Regional Pain Syndrome By Stage
• Complex Regional Pain Syndrome Assessment by Route of Administration
• Complex Regional Pain Syndrome Assessment by Molecule Type
Download Complex Regional Pain Syndrome Sample report to know in detail about the Complex Regional Pain Syndrome treatment market @ Complex Regional Pain Syndrome Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Complex Regional Pain Syndrome Current Treatment Patterns
4. Complex Regional Pain Syndrome – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Complex Regional Pain Syndrome Late-Stage Products (Phase-III)
7. Complex Regional Pain Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Complex Regional Pain Syndrome Discontinued Products
13. Complex Regional Pain Syndrome Product Profiles
14. Complex Regional Pain Syndrome Key Companies
15. Complex Regional Pain Syndrome Key Products
16. Dormant and Discontinued Products
17. Complex Regional Pain Syndrome Unmet Needs
18. Complex Regional Pain Syndrome Future Perspectives
19. Complex Regional Pain Syndrome Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Complex Regional Pain Syndrome Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/